Annals of Oncology 24 (Supplement 9): ix31–ix65, 2013 doi:10.1093/annonc/mdt459.150
Oral Session O3–104
RETROSPECTIVE COHORT STUDY ON THE SAFETY AND EFFICACY OF Pmab FOR mCRC PATIENTS : ANALYSIS OF CLINICAL EARLY PREDICTOR
Y. Sato1, S. Yuki2, Y. Kobayashi2,9, H. Okuda3, Y. Tsuji4, H. Naruse5, M. Koike6, T. Meguro7, M. Nakamura8, Y. Komatsu9 1 The 4th department of Internal Medicine, Sapporo Medical University, 2 Gastroenterology of Hokkaido University Hospital, 3Medical Oncology of Keiyukai Sapporo Hospital, 4Medical Oncology of Tonan Hospital, 5Gastroenterology of Hakodate Municipal Hospital, 6Surgery of KKR Sapporo Medical Center, 7Internal Medicine of Hokkaido Gastroenterology Hospital, 8Gastroenterology of Sapporo City General Hospital, 9Cancer Center of Hokkaido University Hospital
abstracts
Backgrounds: Panitumumab(Pmab) is one of a key part in the treatment of colorectal cancer (CRC). There were few studies about serum marker as an early predictor. We investigated the early plasma CEA, CA19-9, magnesium (Mg2+), calcium (Ca2+) and albumin (Alb) level reductions as a predictor for progression free survival (PFS) and overall survival (OS).
Methods: Two hundred patients ( pts) with metastatic CRC treated by Pmab contained chemotherapy were retrospectively registered from 20 centers in Japan (HGCSG 1002 study). Of these, the pts that were refractory to or intolerant for 5-FU/ irinotecan/ oxaliplatin, and were never administered anti-EGFR-antibody, were included in this analysis. The differences of PFS and OS according to the presence of CEA, CA19-9, Mg2+ , Ca2+ and Alb reductions were evaluated by the log-rank test. Results: Of 67 pts were able to evaluate for this analysis. Pts’ characteristics were as follows: male/female 38/29, median age 64 (range 45-81), ECOG PS (0/1/2- ) 45/17/ 5. Response rate and disease control rate were 16.4% and 65.7%, PFS and OS were 4.3 m and 12.4 m, respectively.An early reduction of CEA at least 40% from the basal value during the course of treatment until the 8th week after start of chemotherapy was significantly correlated with improved OS (P = 0.04) and PFS (P = 0.07), moreover of at least 30% until the 4th week was correlated to longer PFS (P = 0.053). CA19-9 showed similar results to CEA. Mg2+ reduction at least 50% was significantly correlated with improved OS (P = 0.03) and PFS (P = 0.01), but the early reduction was not correlated with OS and PFS. Ca2+ and Alb were not correlated with OS and PFS. Conclusions: An early CEA reduction at least 30% until 8th week and 40% until 4th week was suggested to be a predictor for PFS in Pmab containing chemotherapy for mCRC pts. Although Mg2+ reduction was correlated to clinical outcome, it was not an early predictor for PFS and OS in our study.
© The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email:
[email protected].
